Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC

NCT02200081 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: MGN1703
OTHER: Standard of care

Sponsor

Mologen AG